Seladelpar effect on lipids and muscle safety with concomitant statin use in patients with primary biliary cholangitis: interim results from the open-label ASSURE study with up to 4 years of treatment
| dc.contributor.author | Bowlus, Christopher L. | |
| dc.contributor.author | Yılmaz, Yusuf | |
| dc.contributor.author | Zigmond, Ehud | |
| dc.contributor.author | Blasco, Victor Vargas | |
| dc.contributor.author | Corpechot, Christophe | |
| dc.contributor.author | Diaz-Gonzalez, Alvaro | |
| dc.contributor.author | Vierling, John M. | |
| dc.date.accessioned | 2026-11-02T11:59:32Z | |
| dc.date.issued | 2026 | |
| dc.department | RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | |
| dc.description.abstract | .... | |
| dc.identifier.citation | Bowlus, C. L., Yilmaz, Y., Zigmond, E., Vargas, V., Corpechot, C., Diaz-Gonzalez, A., Proehl, S., Chew, J., Kwon, K. M., Liu, X., Kustra, R. P., & Vierling, J. M. (2026). Seladelpar effect on lipids and muscle safety with concomitant statin use in patients with primary biliary cholangitis: Interim results from the open-label ASSURE study with up to 4 years of treatment. Journal of Hepatology, 84, S302–S303. https://doi.org/10.1016/S0168-8278(26)00988-8 | |
| dc.identifier.doi | 10.1016/S0168-8278(26)00988-8 | |
| dc.identifier.endpage | S303 | |
| dc.identifier.issn | 0168-8278 | |
| dc.identifier.startpage | S302 | |
| dc.identifier.uri | https://doi.org/10.1016/S0168-8278(26)00988-8erişi | |
| dc.identifier.uri | https://hdl.handle.net/11436/13729 | |
| dc.identifier.volume | 84 | |
| dc.identifier.wos | WOS:001799074700014 | |
| dc.identifier.wosquality | Q1 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.institutionauthor | Yılmaz, Yusuf | |
| dc.institutionauthorid | 0000-0003-4518-5283 | |
| dc.language.iso | en | |
| dc.publisher | Elsevier | |
| dc.relation.ispartof | Journal of Hepatology | |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.title | Seladelpar effect on lipids and muscle safety with concomitant statin use in patients with primary biliary cholangitis: interim results from the open-label ASSURE study with up to 4 years of treatment | |
| dc.type | Conference Object |











